The study failed to show a statistically significant reduction in depressive symptoms as measured by the Montgomery-Asberg Depression Rating Scale compared to a placebo, according to a Jan. 2 news release from the company.
The key secondary endpoint, a reduction in anhedonia measured by the Snaith-Hamilton Pleasure Scale, also did not achieve statistical significance. However, navacaprant showed an efficiency signal in female participants with a trend toward improvement in both depressive symptoms and anhedonia though the data were not conclusive.
The drug was generally well-tolerated, with a safety profile comparable to placebo. No adverse events were reported and there were no signals of increased suicidal ideation or behavior.
